Interim report from a phase 2 multicenter study of tazemetostat, an EZH2 inhibitor, in patients with relapsed or refractory B-cell non-Hodgkin lymphomas Meeting Abstract
| Authors: | Morschhauser, F.; Salles, G.; McKay, P.; Tilly, H.; Schmitt, A.; Gerecitano, J.; Johnson, P.; Le Gouill, S.; Dickinson, M. J.; Fruchart, C.; Lamy, T.; Chaidos, A.; Jurczak, W.; Opat, S.; Radford, J.; Zinzani, P. L.; Assouline, S.; Cartron, G.; Clawson, A.; Picazio, N.; Ribich, S.; Blakemore, S. J.; Larus, J.; Miao, H.; Ho, P. T.; Ribrag, V. |
| Abstract Title: | Interim report from a phase 2 multicenter study of tazemetostat, an EZH2 inhibitor, in patients with relapsed or refractory B-cell non-Hodgkin lymphomas |
| Meeting Title: | 14th International Conference on Malignant Lymphoma |
| Journal Title: | Hematological Oncology |
| Volume: | 35 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2017 Jun 14-17 |
| Meeting Location: | Lugano, Switzerland |
| ISSN: | 0278-0232 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2017-06-07 |
| Start Page: | 24 |
| End Page: | 25 |
| Language: | English |
| ACCESSION: | 123459629 |
| DOI: | 10.1002/hon.2437_3 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cin20 |
| DOI/URL: | |
| Notes: | Meeting Abstract: 4 -- Accession Number: 123459629 -- Entry Date: In Process -- Revision Date: 20170608 -- Publication Type: Article -- Supplement Title: Jun2017 Supplement -- Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland -- NLM UID: 8307268. -- Source: cin20 |
